PMID- 28005437
OWN - NLM
STAT- MEDLINE
DCOM- 20170608
LR  - 20181202
IS  - 1520-5762 (Electronic)
IS  - 0363-9045 (Linking)
VI  - 43
IP  - 4
DP  - 2017 Apr
TI  - Self nanoemulsifying granules (SNEGs) of meloxicam: preparation, 
      characterization, molecular modeling and evaluation of in vivo anti-inflammatory 
      activity.
PG  - 600-610
LID - 10.1080/03639045.2016.1275665 [doi]
AB  - Meloxicam, a BCS class II drug belonging to the class of NSAIDs is indicated in 
      conditions of rheumatoid arthritis, ankylosing spondylitis and osteoarthritis in 
      which rapid onset of drug action is desired to reduce inflammation and pain. The 
      objective of the study was to thus develop Self Nanoemulsifying Granules (SNEGs) 
      of Meloxicam (MLX) for enhancement of solubility; and subsequently dissolution 
      rate, thus aiming for a faster onset of action. Preliminary studies along with 
      molecular modeling studies were carried out for selection of appropriate lipids, 
      surfactants and cosurfactants for the development of MLX-loaded Self 
      Nanoemulsifying preconcentrate (SNEP). A charge inducer was incorporated into the 
      formulation so as to increase the solubility of MLX in lipids and hence, drug 
      loading. A three-factor D-optimal mixture design was used for optimization of MLX 
      loaded SNEP. The role of charge inducer in increasing the drug loading of MLX in 
      SNEDDS was studied by molecular dynamics simulation using Desmond. Optimized SNEP 
      was adsorbed onto solid carriers to form SNEGs for improved stability and 
      enhanced flow properties. Physical characterization studies of SNEGs, in vitro 
      release studies, and in vivo evaluation of anti-inflammatory activity of the 
      optimized formulation were performed. All the results indicated that MLX SNEGs 
      can be a promising alternative to conventional oral NSAIDs therapy because of 
      enhanced dissolution characteristics and subsequent rapid onset of action.
FAU - Parekh, Vidhi J
AU  - Parekh VJ
AD  - a Department of Pharmaceutics , Bombay College of Pharmacy, Kalina, Santacruz (E) 
      , Mumbai , India.
FAU - Desai, Namita D
AU  - Desai ND
AD  - a Department of Pharmaceutics , Bombay College of Pharmacy, Kalina, Santacruz (E) 
      , Mumbai , India.
FAU - Shaikh, Mushtaque S
AU  - Shaikh MS
AD  - b Department of Pharmaceutical Analysis , Bombay College of Pharmacy, Kalina, 
      Santacruz (E) , Mumbai , India.
FAU - Shinde, Ujwala A
AU  - Shinde UA
AD  - a Department of Pharmaceutics , Bombay College of Pharmacy, Kalina, Santacruz (E) 
      , Mumbai , India.
LA  - eng
PT  - Journal Article
DEP - 20170117
PL  - England
TA  - Drug Dev Ind Pharm
JT  - Drug development and industrial pharmacy
JID - 7802620
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Drug Carriers)
RN  - 0 (Emulsions)
RN  - 0 (Lipids)
RN  - 0 (Surface-Active Agents)
RN  - 0 (Thiazines)
RN  - 0 (Thiazoles)
RN  - VG2QF83CGL (Meloxicam)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*chemistry/*pharmacology
MH  - Chemistry, Pharmaceutical/methods
MH  - Drug Carriers/chemistry
MH  - Drug Delivery Systems/methods
MH  - Drug Stability
MH  - Emulsions/*chemistry/*pharmacology
MH  - Female
MH  - Lipids/chemistry
MH  - Meloxicam
MH  - Nanoparticles/*chemistry
MH  - Particle Size
MH  - Rats
MH  - Rats, Wistar
MH  - Solubility
MH  - Surface-Active Agents/chemistry
MH  - Thiazines/*chemistry/*pharmacology
MH  - Thiazoles/*chemistry/*pharmacology
OTO - NOTNLM
OT  - Aeroperl(R) 300 pharma
OT  - D-optimal mixture design
OT  - Desmond
OT  - Meloxicam
OT  - Self Nanoemulsifying Drug Delivery Systems
OT  - stearylamine
EDAT- 2016/12/23 06:00
MHDA- 2017/06/09 06:00
CRDT- 2016/12/23 06:00
PHST- 2016/12/23 06:00 [pubmed]
PHST- 2017/06/09 06:00 [medline]
PHST- 2016/12/23 06:00 [entrez]
AID - 10.1080/03639045.2016.1275665 [doi]
PST - ppublish
SO  - Drug Dev Ind Pharm. 2017 Apr;43(4):600-610. doi: 10.1080/03639045.2016.1275665. 
      Epub 2017 Jan 17.